CN101558080A - Aβ肽片段对血管生成的调节 - Google Patents

Aβ肽片段对血管生成的调节 Download PDF

Info

Publication number
CN101558080A
CN101558080A CNA2006800413012A CN200680041301A CN101558080A CN 101558080 A CN101558080 A CN 101558080A CN A2006800413012 A CNA2006800413012 A CN A2006800413012A CN 200680041301 A CN200680041301 A CN 200680041301A CN 101558080 A CN101558080 A CN 101558080A
Authority
CN
China
Prior art keywords
fragment
peptide
peptide fragment
amino acid
varient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800413012A
Other languages
English (en)
Chinese (zh)
Inventor
D·帕里斯
M·J·穆兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roskamp Research LLC
Original Assignee
Roskamp Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roskamp Research LLC filed Critical Roskamp Research LLC
Publication of CN101558080A publication Critical patent/CN101558080A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800413012A 2005-11-10 2006-11-13 Aβ肽片段对血管生成的调节 Pending CN101558080A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73547205P 2005-11-10 2005-11-10
US60/735,472 2005-11-10

Publications (1)

Publication Number Publication Date
CN101558080A true CN101558080A (zh) 2009-10-14

Family

ID=38049186

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800413012A Pending CN101558080A (zh) 2005-11-10 2006-11-13 Aβ肽片段对血管生成的调节

Country Status (8)

Country Link
US (1) US8067372B2 (https=)
EP (1) EP1951750A4 (https=)
JP (1) JP2009516654A (https=)
KR (1) KR20080095836A (https=)
CN (1) CN101558080A (https=)
AU (1) AU2006315686A1 (https=)
CA (1) CA2619455A1 (https=)
WO (1) WO2007059000A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US10882890B2 (en) * 2014-07-25 2021-01-05 Academia Sinica Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105009A (en) * 1959-10-30 1963-09-24 Us Rubber Co Anti-mitotic chemotherapeutic compounds
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
DE667959T1 (de) 1992-10-26 2000-04-20 Dale B Schenk VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID.
WO1994012627A1 (en) 1992-11-25 1994-06-09 Cephalon, Inc. Transgenic animal model for alzheimer's disease
EP0815134B1 (en) * 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
CA2467922A1 (en) * 2001-08-10 2003-02-20 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptides
GB0207362D0 (en) * 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments

Also Published As

Publication number Publication date
WO2007059000A3 (en) 2009-05-14
US8067372B2 (en) 2011-11-29
CA2619455A1 (en) 2007-05-24
US20080031954A1 (en) 2008-02-07
EP1951750A2 (en) 2008-08-06
EP1951750A4 (en) 2009-12-09
KR20080095836A (ko) 2008-10-29
WO2007059000A2 (en) 2007-05-24
JP2009516654A (ja) 2009-04-23
AU2006315686A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
CN101558080A (zh) Aβ肽片段对血管生成的调节
US11306124B2 (en) Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
CA2381323C (en) Amyloid .beta. protein (globular assembly and uses thereof)
ES2281528T3 (es) Peptidos eficaces en el tratamiento de tumores y otros estados que requieren la eliminacion o destruccion de celulas.
US20060147945A1 (en) Novel secreted proteins and their uses
WO2002014358A2 (en) Novel secreted proteins and their uses
US20040038242A1 (en) Novel secreted proteins and their uses
KR20180064434A (ko) 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물
EP1221480B1 (en) Polypeptide humanin inhibiting nerve cell death
JP2018057394A (ja) 癌の処置における使用のための方法及び医薬的組成物
JPWO2001021787A1 (ja) 神経細胞死を抑制するポリペプチド、Ｈｕｍａｎｉｎ
JP2020518261A (ja) Ｃ末端ｃｄｎｆ断片及びｃ末端ｍａｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
EP4110357A1 (en) Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (lrrk2)
JP7069126B2 (ja) 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのｂｃｌ－ｗポリペプチドおよび模倣物
WO2009143489A2 (en) Modulation of angiogenesis by a-beta peptide fragments
JP2005511015A (ja) 神経再生ペプチドおよび脳損傷治療におけるその使用方法
US20100130416A1 (en) Modulation of angiogenesis by a-beta peptide fragments
JP2006503553A (ja) 神経保護ポリペプチドとその使用法
CN115803043A (zh) 钙激活氯离子通道肽激活剂的治疗用途
KR20180023870A (ko) Arl6ip1의 유전성 강직성 하반신마비의 치료 용도
US20250340593A1 (en) Method and composition for treating neurodegenerative disorder
WO2002016578A2 (en) Secreted proteins and methods of using same
KR102267495B1 (ko) 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도
US20030212258A1 (en) Novel secreted proteins and methods of using same
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091014